Abstract: Footwear includes an exterior upper component having a lace-engaging region with medial and lateral side edges. A medial lace engaging slot is defined through the exterior upper component at the medial side edge, and a lateral lace engaging slot is defined through the exterior upper component at the lateral side edge. A medial side foot wrapping band is fixed to a plantar support component and extends inside the exterior upper component toward the medial side edge of the lace-engaging region, and a lateral side foot wrapping band is fixed to the plantar support component and extends inside the exterior upper component toward the lateral side edge of the lace-engaging region. Each of the medial and lateral side foot wrapping bands includes a lace engaging element. A lace engages the medial lace engaging slot, the medial lace engaging element, the lateral lace engaging slot, and the lateral lace engaging element.

Abstract: Provided herein are recombinant nucleic acids that reduce expression of TGFBR1 and/or TGFBR2 and cells comprising such recombinant nucleic acids. Also provided are methods of making and using such cells.

Abstract: A revolutionary and novel design of Earthing Shoes exhibiting an enhanced and environmentally friendly approach to shoe production. The outsole of these shoes is created from a biodegradable, vegan material, while the insole is made of 100% natural hemp, a durable and comfortable organic material. These shoes are equipped with a proprietary and self-energizing crystalized composite embedded in the sole, which provides protection to the biofield of your feet from the hazardous electromagnetic fields (EMF) that are emitted from electronic devices such as laptops and smartphones. These grounding shoes not only shield you from EMF but also reinforce your electromagnetic field, bringing balance to your body. The implications of these shoes on the medical and pharmaceutical industry are undoubtedly significant. Their unique design and exceptional performance make them ideal for individuals who require continuous grounding or require protection from EMF.

Abstract: Footwear or other foot-receiving devices include various conforming fit, stability, and/or “locked down” feel features. The uppers (or foot-covering components) for such articles of footwear (or other foot-receiving devices) may include one or more of: (a) an upper shell defining an interior chamber, wherein the upper shell includes a plantar support surface and sidewalls extending from an outer perimeter of the plantar support surface; (b) a bootie component (e.g., formed as a sock or sock-like garment) received in the interior chamber; (c) one or more foot wrapping bands; and/or (d) an interior midsole within the bootie component. The bootie component and/or the foot wrapping band(s) may be secured to the upper shell at a location inside an outer perimeter of the plantar support surface of the upper shell and beyond the bight line between the sidewalls of the upper and the plantar support surface.

Abstract: A coatings system for improved scratch resistance is provided. The coatings system comprises: 1) a primer comprising a difunctional (meth)acrylate ester monomer, a first multifunctional (meth)acrylate, and a first silane-treated aluminum oxide; and 2) a topcoat comprising a difunctional (meth)acrylate ester monomer, a second multifunctional (meth)acrylate, and a second silane-treated aluminum oxide. Further, the coatings system may be UV curable or another type of radiation curable. A method of preparing the coatings system and an article coated with the coatings system are also described.

Abstract: Described herein are methods useful for detecting and diagnosing pathogen infection using PCR and sequencing.

Abstract: Provided herein are systems comprising one or both of cytokines and/or synthetic pathway activators. Also provided herein are systems comprising one or more suppressors of gene expression, and one or both of cytokines and/or synthetic pathway activators. Also provided are systems of chimeric priming receptors that bind ALPG and/or ALPP, chimeric antigen receptors that bind MSLN, and at least one of one or more suppressors of gene expression, and/or one or both of cytokines and/or synthetic pathway activators; cells expressing such systems; and methods of use thereof.

Abstract: A pouch or pocket may act as a container and may be used to securely hold objects (e.g., cell phone, keys, wallet, etc.) during athletic activity (e.g., running). The pouch may be a standalone item or integrally formed as part of other items. The pouch may hold the object to be stored in place within the pouch or pocket. The pouch may provide some cushioning or impact force attenuation to protect the object being held within the pouch or pocket. Additionally, the pouch may be attached to a garment, such as running clothes. The pouch includes an outer envelope sealable by a closure and a one-way valve with foam layers located inside the pouch. After the object is placed in the pouch, the closure is closed, and the air within the pouch is expelled via the one-way valve by compressing the foam layers from the outside.

Abstract: Described herein are methods useful for detecting and diagnosing pathogen infection using PCR and sequencing.

Abstract: A medical device may be coated with a therapeutic composition that includes a direct oral anticoagulant. An illustrative drug coating composition may comprise an excipient including polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), or poly(vinylidene fluoride)-co-hexafluoropropylene (PVDF-HFP) and a direct oral anticoagulant (DOAC). The illustrative drug coating may be applied to an outer surface of a medical device.

Abstract: A medical device may be coated with a therapeutic composition that includes everolimus. Everolimus crystals may be coated with a mixture of excipients to form encapsulated everolimus crystals suspended in a coating composition. An illustrative coating composition may comprise a mixture of excipients including a bioresorbable or thermo-gelling polymer and a plasticizing agent and a therapeutic agent. The bioresorbable or thermo-gelling polymer may be selected from polycaprolactone (PCL) or poloxamer.

Abstract: A medical device may be coated with a therapeutic composition that includes everolimus. Everolimus crystals may be coated with a mixture of excipients to form encapsulated everolimus crystals suspended in a coating composition. The medical device may be contacted with the coating composition in order to form a coating on the medical device. Coating the everolimus crystals with a mixture of excipients to form encapsulated everolimus crystals suspended in a coating composition may include suspending everolimus crystals in a first solution that includes acetyl tri-butyl citrate (ATBC) and adding a second solution to the first solution, the second solution including ethyl cellulose (EC), the EC mixing with the ATBC and coating the everolimus crystals, thereby forming a coating suspension including coated everolimus crystals in the suspension.

Abstract: Provided herein are recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX. Also provided are systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX, cells expressing such proteins and shRNA, and methods of use thereof.

Abstract: Systems, devices, and methods for closing a large bore access site are disclosed. An example system may include a delivery catheter and a closure device releasably coupled to the delivery catheter. The closure device may include an expandable frame and a patch secured to the expandable frame. The closure device may be configured to shift between a delivery configuration and an expanded configuration. The closure device may be configured to be delivered by the delivery catheter through a blood vessel to a position adjacent to a large bore opening formed in the blood vessel while in the delivery configuration and then shifted to the expanded configuration within the blood vessel so that the patch engages and covers the large bore opening.

Abstract: Provided herein are compositions and methods for producing genetically engineered cells, such as T cells, with an insertion of a cassette at a designated genomic locus. Methods of using the genetically engineered cells for treating or preventing a disease in a subject are also provided.

Abstract: Provided herein are recombinant nucleic acids encoding chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX. Also provided are systems of chimeric priming receptors that bind ALPG/P, chimeric antigen receptors that bind MSLN, and shRNA that target FAS, PTPN2, and/or TOX, cells expressing such proteins and shRNA, and methods of use thereof.

Abstract: Described herein are systems for measuring enzymatic activities. Also described herein are methods for measuring or screening enzymatic activities utilizing the systems described herein.

Abstract: Described herein are systems for measuring enzymatic activities. Also described herein are methods for measuring or screening enzymatic activities utilizing the systems described herein.

Abstract: Various methods are provided for facilitating access to linked information to GPS or short-range wireless equipped devices. One example method may comprise receiving, via a network, an indication of an interaction between a primary device and a third-party device, the indication comprising at least a first element and a second element, the first element indicative of user identification information and the second element indicative of at least one of a location or a bounded region, determining, as a function of at least the first element and the second element, a data object that upon validation is configured for use a subsequent interaction, and transmitting, to a mobile device, an electronic communication comprising an indication, configured for rendering on the mobile device, of the data object.

Abstract: Provided herein are safe harbor loci and methods for identifying and using safe harbor loci to engineer cells to express transgenes. The safe harbor loci exhibit increased transgene knock-in efficiency and allow for increased, stable expression of transgenes in engineered cells. Guide ribonucleic acids (gRNAs) may be used for insertion of transgenes in the safe harbor loci.